Use of Rituximab Compared to Anti-Tnf Agents As Second and Third Line Therapy in Patients with Rheumatoid Arthritis: A Report from the rhumadata® Clinical Database and registry.

被引：0

作者：

Choquette, Denis ^{[1
]}

Raynauld, Jean-Pierre ^{[1
]}

Pelletier, Jean Pierre ^{[1
]}

Haraoui, Boulos ^{[1
]}

Bessette, Louis ^{[2
]}

Villeneuve, Edith ^{[1
]}

Remillard, Marie-Anais ^{[1
]}

Fortin, Isabelle ^{[3
]}

Sauvageau, Diane ^{[1
]}

Coupal, Louis ^{[1
]}

机构：

[1] IRM, Montreal, PQ, Canada

[2] CORQ, Quebec City, PQ, Canada

[3] CREQ, Rimouski, PQ, Canada

来源：

ARTHRITIS & RHEUMATOLOGY | 2014年 / 66卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

1535

引用

页码：S676 / S676

页数：1

共 50 条

[1] Use of Rituximab Compared to Anti-TNF Agents as Second and Third Line Therapy in Patients with Rheumatoid Arthritis: A Report from the RHUMADATA® Clinical Database and Registry
Choquette, Denis
Bessette, Louis
Fortin, Isabelle
Haraoui, Boulos
Pelletier, Jean-Pierre
Raynauld, Jean-Pierre
Remillard, Marie-Anais
Massicotte, Frederic
Sauvageau, Diane
Villeneuve, Edith
Coupal, Louis
JOURNAL OF RHEUMATOLOGY, 2015, 42 (07) : 1298 - 1298
[2] USE OF RITUXIMAB COMPARED TO ANTI-TNF AGENTS AS SECOND AND THIRD LINE THERAPY IN PATIENTS WITH RHEUMATOID ARTHRITIS. A REPORT FROM THE RHUMADATA® CLINICAL DATABASE AND REGISTRY
Choquette, D.
Raynauld, J. -P.
Bessette, L.
Fortin, I.
Haraoui, B.
Pelletier, J. P.
Remillard, M. -A.
Sauvageau, D.
Villeneuve, E.
Coupal, L.
ANNALS OF THE RHEUMATIC DISEASES, 2014, 73 : 881 - 881
[3] Use of Rituximab Compared to Anti-TNF Agents As Second and Third Line Therapy in Patients with Rheumatoid Arthritis: 6-Year Follow-up Report from the Rhumadata® Clinical Database and Registry
Choquette, Denis
Bessette, Louis
Haraoui, Boulos
Massicotte, Frederic
Pelletier, Jean-Pierre
Raynauld, Jean-Pierre
Remillard, Marie-Anais
Sauvageau, Diane
Villeneuve, Edith
Coupal, Louis
Brown, Jacques
Turcotte, Angele
ARTHRITIS & RHEUMATOLOGY, 2015, 67
[4] Use of Rituximab Compared to Anti-TNF Agents as Second and Third Line Therapy in Patients with Rheumatoid Arthritis. A 6 Year Follow-Up Report from the Rhumadata Clinical Database and Registry
Choquette, Denis
Bessette, Louis
Brown, Jacques
Haraoui, Boulos
Massicotte, Frederic
Pelletier, Jean-Pierre
Raynauld, Jean-Pierre
Remillard, Marie-Anais
Sauvageau, Diane
Villeneuve, Edith
Coupal, Louis
JOURNAL OF RHEUMATOLOGY, 2016, 43 (06) : 1212 - 1213
[5] USE OF RITUXIMAB COMPARED TO ANTI-TNF AGENTS AS SECOND AND THIRD-LINE THERAPY IN PATIENTS WITH RHEUMATOID ARTHRITIS. A 6-YEAR FOLLOW-UP REPORT FROM THE RHUMADATA® CLINICAL DATABASE AND REGISTRY
Raynauld, J. -P.
Bessette, L.
Brown, J.
Coupal, L.
Haraoui, B.
Massicotte, F.
Pelletier, J. -P.
Remillard, M. -A.
Sauvageau, D.
Villeneuve, E.
Choquette, D.
ANNALS OF THE RHEUMATIC DISEASES, 2016, 75 : 190 - 190
[6] Use Of Rituximab As Second Line Biologic Agent Compared With Adalimumab, Etanercept and Infliximab In Patients With Rheumatoid Arthritis. A Report From The Rhumadata® Clinical Database and Registry
Bessette, Louis
Choquette, Denis
Sauvageau, Diane
Haraoui, Boulos
Pelletier, Jean Pierre
Raynauld, Jean-Pierre
Villeneuve, Edith
Coupal, Louis
ARTHRITIS AND RHEUMATISM, 2013, 65 : S187 - S187
[7] Better Retention Rate of Rituximab Vs Anti-Tnf Agents As Second Line therapy in RA Patients Failing a First Anti-Tnf Agents: Results From the Rhumadata® Registry
Choquette, D.
ARTHRITIS AND RHEUMATISM, 2011, 63 (10): : S859 - S859
[8] MODELING THE COST-EFFECTIVENESS OF RITUXIMAB USE COMPARED TO TUMOR NECROSIS FACTOR INHIBITORS (ANTI-TNF) AGENTS AS A SECOND-LINE THERAPY IN PATIENTS WITH RHEUMATOID ARTHRITIS (RA) IN QUEBEC, CANADA USING RHUMADATA REGISTRY DATA
Lopatina, E.
Marshall, D. A.
Coupal, L.
Choquette, D.
VALUE IN HEALTH, 2017, 20 (05) : A147 - A147
[9] Modeling the Cost-effectiveness of Rituximab Use Compared to Tumor Necrosis Factor Inhibitors (anti-TNF) Agents as a Second-line Therapy in Patients with Rheumatoid Arthritis (RA) in Quebec, Canada Using RHUMADATA Registry Data
Lopatina, Elena
Choquette, Denis
Coupal, Louis
Marshall, Deborah
JOURNAL OF RHEUMATOLOGY, 2017, 44 (06) : 882 - 883
[10] Comparing Abatacept to Adalimumab, Etanercept and Infliximab As First Line Agents in Patients with Rheumatoid Arthritis. Experience from the Rhumadata® Clinical Database and Registry.
Choquette, Denis
Bessette, Louis
Fortin, Isabelle
Haraoui, Boulos
Pelletier, Jean Pierre
Raynauld, Jean-Pierre
Remillard, Marie-Anais
Sauvageau, Diane
Villeneuve, Edith
Coupal, Louis
ARTHRITIS & RHEUMATOLOGY, 2014, 66 : S676 - S677

← 1 2 3 4 5 →